Published in Am J Physiol Endocrinol Metab on July 08, 2008
Basal alpha-cell up-regulation in obese insulin-resistant adolescents. J Clin Endocrinol Metab (2010) 0.89
Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity (Silver Spring) (2015) 0.85
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. Diabetes (2008) 0.82
2. Hypoglycemia Detection. Transl Endocrinol Metab (2012) 0.78
Hypoglycemic detection at the portal vein: absent in humans or yet to be elucidated? Diabetes (2009) 0.76
Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 27.52
Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 3.42
Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism (1981) 2.62
Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes (1995) 2.30
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab (2002) 2.18
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes (1988) 1.89
The locus for hypoglycemic detection shifts with the rate of fall in glycemia: the role of portal-superior mesenteric vein glucose sensing. Diabetes (2008) 1.84
Perceived symptoms in the recognition of hypoglycemia. Diabetes Care (1993) 1.53
Effect of glucagon on glucose production during insulin deficiency in the dog. J Clin Invest (1978) 1.52
Assay of plasma catecholamines by liquid chromatography with electrochemical detection. Anal Biochem (1981) 1.51
Novel glucosensor for hypoglycemic detection localized to the portal vein. Diabetes (1997) 1.36
Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia-induced hormonal counterregulation. J Clin Invest (2006) 1.30
Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol (1993) 1.26
Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. J Clin Invest (1989) 1.20
Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes (1997) 1.17
Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes (2000) 1.16
Primacy of liver glucosensors in the sympathetic response to progressive hypoglycemia. Proc Natl Acad Sci U S A (1994) 1.15
Metabolic sensing neurons and the control of energy homeostasis. Physiol Behav (2006) 1.14
Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. Diabetes (2000) 1.09
Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia (2005) 1.07
Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes (2000) 1.06
Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care (2004) 1.03
Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog. Am J Physiol (1983) 1.02
Differential gender responses to hypoglycemia are due to alterations in CNS drive and not glycemic thresholds. Am J Physiol Endocrinol Metab (2000) 1.01
Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care (2005) 1.01
Hypoglycemic detection does not occur in the hepatic artery or liver: findings consistent with a portal vein glucosensor locus. Diabetes (2001) 0.96
Celiac-superior mesenteric ganglionectomy, but not vagotomy, suppresses the sympathoadrenal response to insulin-induced hypoglycemia. Diabetes (2005) 0.94
Impaired glucagon response to sympathetic nerve stimulation in the BB diabetic rat: effect of early sympathetic islet neuropathy. Am J Physiol Endocrinol Metab (2003) 0.92
The role of hepatic portal glucose sensing in modulating responses to hypoglycaemia in man. Diabetologia (2002) 0.89
Metabolic sensors mediate hypoglycemic detection at the portal vein. Diabetes (2006) 0.88
The role of glucosensing neurons in the detection of hypoglycemia. Diabetes Technol Ther (2004) 0.87
Oral glucose augments the counterregulatory hormone response during insulin-induced hypoglycemia in humans. J Clin Endocrinol Metab (2001) 0.87
Portal vein hypoglycemia is essential for full induction of hypoglycemia-associated autonomic failure with slow-onset hypoglycemia. Am J Physiol Endocrinol Metab (2007) 0.84
Unlike mice, dogs exhibit effective glucoregulation during low-dose portal and peripheral glucose infusion. Am J Physiol Endocrinol Metab (2003) 0.84
Enteral infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia. Am J Physiol Endocrinol Metab (2003) 0.83
The increase in sympathetic nerve activity after glucose ingestion is reduced in type I diabetes. Clin Sci (Lond) (2000) 0.81
Effects of drink volume and glucose load on gastric emptying and postprandial blood pressure in healthy older subjects. Am J Physiol Gastrointest Liver Physiol (2005) 0.78
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
Autonomic contribution to blood pressure and metabolism in obesity. Hypertension (2006) 2.25
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care (2010) 1.71
The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29
Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes (2004) 1.20
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab (2011) 1.11
Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2006) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Leptin: metabolic control and regulation. J Diabetes Complications (2003) 1.03
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes (2003) 1.01
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs (2014) 1.00
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes (2003) 0.98
Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes (2008) 0.97
Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone (2006) 0.93
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes (2008) 0.90
Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev (2005) 0.89
Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes (2003) 0.89
Hypoglycemia associated autonomic failure. Clin Auton Res (2002) 0.88
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Curr Diabetes Rev (2013) 0.87
Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.87
Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. Diabetes (2010) 0.86
Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother (2011) 0.86
Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab (2006) 0.85
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes. Diabetes (2009) 0.85
Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care (2010) 0.85
Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes. J Clin Endocrinol Metab (2002) 0.84
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications (2007) 0.84
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2015) 0.84
Effect of sex on counterregulatory responses to exercise after antecedent hypoglycemia in type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 0.84
Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab (2005) 0.83
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats. Am J Physiol Endocrinol Metab (2007) 0.83
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2013) 0.82
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol (2011) 0.82
Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther (2011) 0.82
NO synthase inhibition increases aldosterone in humans. Hypertension (2004) 0.82
The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2010) 0.82
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther (2012) 0.81
The effects of dehydroepiandrosterone sulfate on counterregulatory responses during repeated hypoglycemia in conscious normal rats. Diabetes (2004) 0.80
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.79
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am J Physiol Endocrinol Metab (2005) 0.79
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep (2008) 0.78
Caffeine: a cause of insulin resistance? Diabetes Care (2002) 0.78
Physical activity in adolescents with type 1 diabetes: is more better for glycemic control? Pediatr Diabetes (2009) 0.78
Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab (2008) 0.77
Hypoglycemia and vascular disease. Clin Chem (2010) 0.76
Diabetes: Hypoglycemia-a new approach to an old problem. Nat Rev Endocrinol (2009) 0.76
New concepts in diabetes: how multihormonal regulation can improve glycemic control. J Manag Care Pharm (2004) 0.76
Metabolic consequences of exercise-associated autonomic failure. Exerc Sport Sci Rev (2006) 0.76
Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract (2004) 0.76
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2012) 0.76
The cardiovascular effects of insulin. Expert Opin Drug Saf (2014) 0.75
Discontinued in 2013: diabetic drugs. Expert Opin Investig Drugs (2014) 0.75
Forebrain and hindbrain effects of ethanol on counterregulatory responses to hypoglycemia in conscious rats. Metabolism (2007) 0.75
Prior exercise and the response to insulin-induced hypoglycemia in the dog. Am J Physiol Endocrinol Metab (2002) 0.75
Leptin responses to antecedent exercise and hypoglycemia in healthy and type 1 diabetes mellitus men and women. J Diabetes Complications (2003) 0.75
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2014) 0.75
The endocannabinoid system as a target for obesity treatment. Clin Cornerstone (2008) 0.75
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation. Clin Cornerstone (2006) 0.75